Nos publications - Institut Roche

Thomas, G., Chardès, T., Gaborit, N., Mollevi, C., Leconet, W., Robert, B., Radosevic-Robin, N., Penault-Llorca, F., Gongora, C., Colombo, P. E., Lazrek, Y., Bras-Goncalves, R., Savina, A., Azria, D., Bazin, H., Pèlegrin, A., & Larbouret, C. (2014).

HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. Oncotarget, 5(16), 7138–7148.

https://doi.org/10.18632/oncotarget.2231

Viger, L., Denis, F., Rosalie, M., & Letellier, C. (2014).

A cancer model for the angiogenic switch. Journal of theoretical biology, 360, 21–33.

https://doi.org/10.1016/j.jtbi.2014.06.020

Decaup, E., Duault, C., Bezombes, C., Poupot, M., Savina, A., Olive, D., & Fournié, J. J. (2014).

Phosphoantigens and butyrophilin 3A1 induce similar intracellular activation signaling in human TCRVγ9+ γδ T lymphocytes. Immunology letters, 161(1), 133–137.

https://doi.org/10.1016/j.imlet.2014.05.011

Rossille, D., Gressier, M., Damotte, D., Maucort-Boulch, D., Pangault, C., Semana, G., Le Gouill, S., Haioun, C., Tarte, K., Lamy, T., Milpied, N., Fest, T., Groupe Ouest-Est des Leucémies et Autres Maladies du Sang, & Groupe Ouest-Est des Leucémies et Autres Maladies du Sang (2014).

High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia, 28(12), 2367–2375.

https://doi.org/10.1038/leu.2014.137

Bieche, I., Vacher, S., Vallerand, D., Richon, S., Hatem, R., De Plater, L., Dahmani, A., Némati, F., Angevin, E., Marangoni, E., Roman-Roman, S., Decaudin, D., & Dangles-Marie, V. (2014).

Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings. BMC cancer, 14, 178.

https://doi.org/10.1186/1471-2407-14-178

Maillet, D., Goulvent, T., Rimokh, R., Vacher-Lavenu, M. C., Pautier, P., Alexandre, J., Pujade-Laurraine, E., Devouassoux-Shisheboran, M., Treilleux, I., Ray-Coquard, I., & Savina, A. (2014).

Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO network. Gynecologic oncology, 132(1), 181–187.

https://doi.org/10.1016/j.ygyno.2013.10.013

Gravelle, P., Jean, C., Familiades, J., Decaup, E., Blanc, A., Bezombes-Cagnac, C., Laurent, C., Savina, A., Fournié, J. J., & Laurent, G. (2014).

Cell growth in aggregates determines gene expression, proliferation, survival, chemoresistance, and sensitivity to immune effectors in follicular lymphoma. The American journal of pathology, 184(1), 282–295.

https://doi.org/10.1016/j.ajpath.2013.09.018

Corazao-Rozas, P., Guerreschi, P., Jendoubi, M., André, F., Jonneaux, A., Scalbert, C., Garçon, G., Malet-Martino, M., Balayssac, S., Rocchi, S., Savina, A., Formstecher, P., Mortier, L., Kluza, J., & Marchetti, P. (2013).

Mitochondrial oxidative stress is the Achille’s heel of melanoma cells resistant to Braf-mutant inhibitor. Oncotarget, 4(11), 1986–1998.

https://doi.org/10.18632/oncotarget.1420

Combes, F.P., Retout, S., Frey, N. et al.

Prediction of Shrinkage of Individual Parameters Using the Bayesian Information Matrix in Non-Linear Mixed Effect Models with Evaluation in Pharmacokinetics. Pharm Res 30, 2355–2367 (2013).

https://doi.org/10.1007/s11095-013-1079-3